The incidence of secondary malignancies following chemotherapy is progressively increasing, mostly due to prolonged survival of patients treated for primary cancer. So far, only 3 cases of solid cancer following busulphan administration have been reported. We describe the case of a patient who developed a renal cancer after 4 years of busulphan treatment for chronic myeloid leukemia. Immunosuppression rather than mutagenesis seems to be responsible for the emergence of second solid cancers in patients receiving busulphan.
BoivinJ.F.: Second cancers and other late side effects of cancer treatment.Cancer, 65: 770–775, 1990.
3.
ChabnereB.A.: Second neoplasm: a complication of cancer chemotherapy.N. Engl. J. Med., 297: 213, 1977.
4.
Henry-AmarM., DietrichP.Y.: Acute leukemia after the treatment of Hodgkin's disease.Hematol. Oncol. Clinics North Am., 7: 369–387, 1993.
5.
IurloA., MecucciC., Van OrshovenA., MichauxJ.L., BoogaertsM., NoensL., BoslyA., LouwagieA., Van den BergheH.: Cytogenetic and clinical investigations in 76 cases with therapy related leukemia and myelodysplastic syndrome.Cancer Genet. Cytogenet., 43: 227–241, 1989.
6.
KinlenL.J.: Immunologic factors. In: Cancer epidemiology and prevention.SchottenfeldD., FraumeniJ.F.Jr., (Eds.), pp. 494–505. W.B. Saunders, Philadelphia, 1982.
7.
KyleR.: Second malignancies associated with chemotherapeutic agents.Semin. Oncol., 9: 131–142, 1982.
8.
Le BeauM.M., AlbainK.S., LarsonR.A., VardimanJ.M., DavisE.M., BloughR.R., GolombH.M., RoweleyJ.: Clinical and cytogenetic correlation in 63 patients with therapy-related myelodyplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J.Clin. Oncol., 4: 325–345, 1986.
9.
MichelsS.D., McKennaR.W., ArthurC.D., BrunningR.D.: Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphological study of 65 cases.Blood, 65: 1364–1372, 1985.
10.
ShulmanL.N.: The biology of alkylating agent cellular injury.Hematol. Oncol. Clinics North Am., 7: 325–335, 1993.
11.
SparaventiG., MannaA., MurettoP., PazzagliaC., PalazziM., PorcelliniA.: Malignant melanoma of the glans penis in a chronic myeloid leukemia patient after busulfan therapy.Tumori, 73: 645–648, 1987.
12.
StortiS., PaganoL., MarraR., D'AddosioA., RicercaB.M., ManciniR., BizziB.: Gastrointestinal cancer in patients with chronic myeloid leukemia on busulfan treatment.Am. J. Hematol.,35–90, 1990.
13.
TurckerM.A., ColemanC.N., CoxR.S., VargheseA., RosembergS.A.: Risk of second cancers after treatment for Hodgkin's disease.N. Engl. J. Med., 318: 76–81, 1988.
